Actively Recruiting

Age: 40Years - 99Years
All Genders
Healthy Volunteers
ID05468905

China Longitudinal Aging and Cognitive Impairment Study

Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2022-07-21

4000

Participants Needed

2

Research Sites

52 weeks

Total Duration

On this page

Sponsors

S

Second Affiliated Hospital, School of Medicine, Zhejiang University

Lead Sponsor

T

The Central Hospital of Lishui City

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are conducting a multi-center longitudinal study focused on aging and cognitive impairment, including groups with normal cognitive aging, subjective cognitive impairment, mild cognitive impairment, Alzheimer's disease, and vascular cognitive impairment. The study aims to create a detailed database with epidemiological, neuropsychological, laboratory, imaging, and biological sample data. It also seeks to identify risk factors and biomarkers related to Alzheimer's disease and other dementias, as well as to measure conversion rates between cognitive stages over time. Participants will be categorized into one of five cohorts based on cognitive status and diagnostic criteria. They will be followed for up to five years, with data collected at baseline and follow-up visits. Collected data include medical histories, MRI and PET scans, genetic information, and biological samples such as blood, cerebrospinal fluid, and urine. This study does not involve any interventions but focuses on observing and tracking changes in cognition and related biomarkers. During the study, participants will undergo comprehensive assessments including cognitive testing, imaging scans, and biomarker analysis. Researchers will monitor the prevalence and incidence of cognitive impairment and dementia, the progression from normal cognition to more severe conditions, and relevant biomarkers in fluid and imaging studies. Additional measures include tracking gut microbiota and gait changes. The total involvement may last up to five years, with ongoing evaluations to better understand aging and cognitive decline.

CONDITIONS

Brief Title

China Longitudinal Aging and Cognitive Impairment Study

Who Can Participate

Age: 40Years - 99Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 40 and 99 years
  • Participants with normal cognitive function (MMSE ≥ 22) without impairment
  • Participants with subjective cognitive concerns without dementia
  • Participants diagnosed with mild cognitive impairment based on established criteria
  • Participants aged 50 and older diagnosed with Alzheimer's disease
  • Participants diagnosed with vascular cognitive impairment according to specified vascular and cognitive criteria
  • Ability to complete required examinations and sign informed consent
Not Eligible

You will not qualify if you...

  • Presence of diseases causing cognitive impairment such as dementia with Lewy bodies, frontotemporal dementia, Parkinson's disease dementia, severe brain trauma, or cerebrovascular disease with symptoms
  • History of severe central nervous system infections, autoimmune encephalitis, or epilepsy
  • Systemic diseases affecting the brain, including severe liver or kidney dysfunction
  • History of hereditary diseases affecting cognition like Huntington's disease or Down syndrome
  • Long-term heavy alcohol use
  • History of severe pulmonary or cardiovascular disease
  • Immune-related diseases affecting the brain
  • Metabolic or endocrine disorders requiring new or adjusted treatment
  • Unstable psychosis or long-term antipsychotic use
  • Recent active malignant tumors
  • Contraindications for MRI or inability to cooperate with imaging
  • Illiteracy or significant sensory impairments
  • Refusal to participate or withdraw from the study
  • History of stroke with neurological deficits or other neurological diseases causing brain dysfunction
  • Systemic diseases causing cognitive impairment
  • Mental or neurodevelopmental retardation
  • Refusal to provide blood samples or sign consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Baseline Assessment

Duration - Up to 1 month

Participants undergo collection of epidemiological data, medical history, imaging scans (MRI and PET), genetic information, and biological samples.

1 baseline visit (in-person)

Long-term Monitoring

Duration - Up to 5 years

Participants are followed up over time with repeated assessments to monitor cognitive status and collect data including imaging and biological samples.

Follow-up visits at designated time points for up to 5 years

Trial Site Locations

Total: 2 locations

1

Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China, 310009

Actively Recruiting

2

Zhejiang Lishui central Hospital

Lishui, Zhejiang, China, 323000

Actively Recruiting

Loading map...

Research Team

Q

Qing-Qing Tao, M.D.

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

5

Similar Trials

Comparison of Cardiac [18F]-MFBG PET Versus [123I]-MIBG SPEC...

Parkinson Disease

Actively Recruiting

2 locations

An Open-label, Non-randomized, Multi-center Pivotal Phase 3 ...

Alzheimer Disease

Actively Recruiting

25 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here